Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 3/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25321972 | 1.00 | FABP7 (0.41) | FABP7RIPK1SCN9AGABRA1GABRG2 | |
| SCHEMBL25920109 | 1.00 | FABP7 (0.41) | FABP7RIPK1SCN9AGABRA1GABRG2 | |
| SCHEMBL25324933 | 0.89 | FABP7 (0.36) | FABP7RIPK1SCN9AGABRA1GABRG2 | |
| SCHEMBL25322230 | 0.86 | PRMT5 (0.47) | FABP7RIPK1SCN9APRMT5WDR77 | |
| SCHEMBL30470748 | 0.86 | PRMT5 (0.47) | FABP7RIPK1SCN9APRMT5WDR77 | |
| SCHEMBL25322227 | 0.86 | PRMT5 (0.47) | FABP7RIPK1SCN9APRMT5WDR77 | |
| SCHEMBL25321489 | 0.80 | RIPK1 (0.43) | RIPK1PRMT5WDR77TACR1 | |
| SCHEMBL25920110 | 0.80 | RIPK1 (0.43) | RIPK1PRMT5WDR77TACR1 | |
| SCHEMBL25321486 | 0.80 | RIPK1 (0.43) | RIPK1PRMT5WDR77TACR1 | |
| SCHEMBL29081332 | 0.79 | PRMT5 (0.47) | FABP7RIPK1PRMT5WDR77TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | FABP7 4858/4885RIPK1 4616/4885SCN9A 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.